Cargando…

Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study

BACKGROUND: Bladder neuroendocrine carcinomas (BNECs) are relatively a rare type of tumor. The aim of this study was to examine the clinicopathological characteristics and predictors of survival outcomes of patients with BNECs based on the analysis of the national Surveillance, Epidemiology, and End...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Quan, Lu, Youyi, Xu, Shigao, Shi, Qun, Guo, Baoyu, Guo, Zhe, Huang, Tianbao, Wu, Yinxia, Yu, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190820/
https://www.ncbi.nlm.nih.gov/pubmed/30349380
http://dx.doi.org/10.2147/CMAR.S175286
_version_ 1783363628471156736
author Niu, Quan
Lu, Youyi
Xu, Shigao
Shi, Qun
Guo, Baoyu
Guo, Zhe
Huang, Tianbao
Wu, Yinxia
Yu, Junjie
author_facet Niu, Quan
Lu, Youyi
Xu, Shigao
Shi, Qun
Guo, Baoyu
Guo, Zhe
Huang, Tianbao
Wu, Yinxia
Yu, Junjie
author_sort Niu, Quan
collection PubMed
description BACKGROUND: Bladder neuroendocrine carcinomas (BNECs) are relatively a rare type of tumor. The aim of this study was to examine the clinicopathological characteristics and predictors of survival outcomes of patients with BNECs based on the analysis of the national Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: Kaplan–Meier analysis with log-rank test was used for survival comparisons. Multivariate Cox regression model was employed to analyze the effect of different treatments on overall survival (OS) and cancer-specific survival (CSS). RESULTS: A total of 910 patients were identified between 2004 and 2014. Overall, 648 (71.2%) patients had small cell neuroendocrine carcinoma (SCNEC), 35 (3.8%) had large cell neuroendocrine carcinoma (LCNEC), 10 (1.1%) had carcinoid tumor (well-differentiated neuroendocrine tumor), 16 (1.8%) had paraganglioma/pheochromocytoma (PGL/PHEO), 619 (68.0%) had a poorly differentiated or undifferentiated histology grade, 214 (23.5%) presented with metastatic disease, 586 (64.4%) underwent transurethral ablation/destruction for bladder tumor, and 245 (26.9%) had partial/total cystectomy. Cystectomy+chemotherapy+radiotherapy (CCR) has the highest long-term survival rate among various treatments. The 1-, 3-, and 5-years CSS of CCR were 56%, 56%, and 56%, respectively. By using multivariable Cox proportional hazard model, age, histology, N stage, SEER stage, tumor size, radiotherapy, chemotherapy, and local treatment of the primary site were identified as independent predictors for OS and CSS; all P<0.05. CONCLUSION: In BNEC, SCNEC has an absolute advantage in number. SCNEC/LCNEC tend to be older men. PGL/PHEO and carcinoid tumors have younger mean ages, earlier tumor stages, and better prognosis than SCNEC/LCNEC. Surgery, radiotherapy and chemotherapy are better than conservative treatment. However, whatever cystectomy or bladder sparing, chemotherapy should be a major component of treatment.
format Online
Article
Text
id pubmed-6190820
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61908202018-10-22 Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study Niu, Quan Lu, Youyi Xu, Shigao Shi, Qun Guo, Baoyu Guo, Zhe Huang, Tianbao Wu, Yinxia Yu, Junjie Cancer Manag Res Original Research BACKGROUND: Bladder neuroendocrine carcinomas (BNECs) are relatively a rare type of tumor. The aim of this study was to examine the clinicopathological characteristics and predictors of survival outcomes of patients with BNECs based on the analysis of the national Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: Kaplan–Meier analysis with log-rank test was used for survival comparisons. Multivariate Cox regression model was employed to analyze the effect of different treatments on overall survival (OS) and cancer-specific survival (CSS). RESULTS: A total of 910 patients were identified between 2004 and 2014. Overall, 648 (71.2%) patients had small cell neuroendocrine carcinoma (SCNEC), 35 (3.8%) had large cell neuroendocrine carcinoma (LCNEC), 10 (1.1%) had carcinoid tumor (well-differentiated neuroendocrine tumor), 16 (1.8%) had paraganglioma/pheochromocytoma (PGL/PHEO), 619 (68.0%) had a poorly differentiated or undifferentiated histology grade, 214 (23.5%) presented with metastatic disease, 586 (64.4%) underwent transurethral ablation/destruction for bladder tumor, and 245 (26.9%) had partial/total cystectomy. Cystectomy+chemotherapy+radiotherapy (CCR) has the highest long-term survival rate among various treatments. The 1-, 3-, and 5-years CSS of CCR were 56%, 56%, and 56%, respectively. By using multivariable Cox proportional hazard model, age, histology, N stage, SEER stage, tumor size, radiotherapy, chemotherapy, and local treatment of the primary site were identified as independent predictors for OS and CSS; all P<0.05. CONCLUSION: In BNEC, SCNEC has an absolute advantage in number. SCNEC/LCNEC tend to be older men. PGL/PHEO and carcinoid tumors have younger mean ages, earlier tumor stages, and better prognosis than SCNEC/LCNEC. Surgery, radiotherapy and chemotherapy are better than conservative treatment. However, whatever cystectomy or bladder sparing, chemotherapy should be a major component of treatment. Dove Medical Press 2018-10-11 /pmc/articles/PMC6190820/ /pubmed/30349380 http://dx.doi.org/10.2147/CMAR.S175286 Text en © 2018 Niu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Niu, Quan
Lu, Youyi
Xu, Shigao
Shi, Qun
Guo, Baoyu
Guo, Zhe
Huang, Tianbao
Wu, Yinxia
Yu, Junjie
Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
title Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
title_full Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
title_fullStr Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
title_full_unstemmed Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
title_short Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
title_sort clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190820/
https://www.ncbi.nlm.nih.gov/pubmed/30349380
http://dx.doi.org/10.2147/CMAR.S175286
work_keys_str_mv AT niuquan clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT luyouyi clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT xushigao clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT shiqun clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT guobaoyu clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT guozhe clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT huangtianbao clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT wuyinxia clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy
AT yujunjie clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy